Clinical Trial Update: PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating PEG-rhG-CSF in patients with malignant solid tumors undergoing chemotherapy has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• PEG-rhG-CSF (pegylated recombinant human granulocyte colony-stimulating factor)

Snippet

Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Conditions: Malignant Solid Tumors | Phase 4 | Status: COMPLETED